TIMP-2產品信息
別稱:CSC-21K,TIMP2
物種:Human
屬性:Protein
標記:Unconjugated
內毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>95% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
重構方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
![1.jpg 1.jpg](/SupplyImg/2024-05-15/6385138036049334254387663.jpg)
TIMP-2分子背景
TIMP metallopeptidase inhibitor 2 is also known as TIMP2, which belongs to the protease inhibitor I35 (TIMP) family. This family protein are natural inhibitors of the matrix metalloproteinases, a group of peptidases involved in degradation of the extracellular matrix. The TIMP family encompasses four members ( TIMP1, TIMP2, TIMP3, TIMP4 ), and they inhibit most MMPs by forming non-covalent binary complex. In addition to an inhibitory role against metalloproteinases, TIMP2 has a unique role among TIMP family members in its ability to directly suppress the proliferation of endothelial cells. As a result, TIMP-2 may be critical to the maintenance of tissue homeostasis by suppressing the proliferation of quiescent tissues in response to angiogenic factors, and by inhibiting protease activity in tissues undergoing remodelling of the extracellular matrix.
![通用.jpg 通用.jpg](/SupplyImg/2024-05-15/6385138037034828524832270.jpg)
關鍵字: TIMP-2;TIMP-2蛋白;TIMP-2重組蛋白;ACRO;百普賽斯;
百普賽斯集團ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產業(yè)領域提供關鍵生物試劑產品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個城市設有辦公室、研發(fā)中心及生產基地。目前累計服務客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學等。